Düsseldorf (ots) - Zur Mitgliederversammlung in Potsdam am 10. und 11. März präsentiert der Zentralverband ...
Accuray Announces First Radiation Therapy Systems Installed in Qatar, Latvia and Bulgaria
Sunnyvale, California (ots/PRNewswire) - Premier Qatar, Latvian Cancer Centers to Offer Patients Treatment with the CyberKnife® System; Leading Bulgarian Hospital to Provide Treatment with the TomoTherapy® System
Accuray Incorporated (NASDAQ: ARAY) announced today that the first centers in Qatar, Latvia, and Bulgaria are now equipped with its radiation therapy technology, demonstrating continued momentum in adoption of its devices in Europe, India, the Middle East and Africa (EIMEA). The CyberKnife® and TomoTherapy® Systems are now used in more than 40 countries to treat patients across the full spectrum of radiation therapy cases, from routine to complex, including brain, breast, lung, head and neck, pancreas and prostate. With an increasing number of centers installing the systems, more patients will have the opportunity to benefit from the extremely precise radiation treatments they deliver.
For more information on the CyberKnife and TomoTherapy Systems visit http://www.accuray.com.
Qatar: first CyberKnife System in the Gulf Cooperation Council
The National Center for Cancer Care and Research, located in Doha, is the first center in the region to be equipped with Accuray technology. The installation of the CyberKnife M6(TM) Series makes it possible for patients to receive treatment with one of the most advanced radiation therapy systems on the market.
Latvia: first CyberKnife System in the Baltic countries
The stereotactic radiosurgery center (SRC) 'Sigulda,' located in Sigulda, is the first center to offer CyberKnife M6 System treatments in the Baltic region. SRC 'Sigulda' plans to use the system to treat both oncological and non-oncological diseases.
The CyberKnife M6 Series delivers radiosurgery and stereotactic body radiation therapy (SBRT), enabling precise, high-quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision.
Bulgaria: first TomoTherapy System in the country
The New Radiotherapy Clinic in SBALO- Specialized Hospital for Active Treatment in Oncology, located in Sofia, will be the first hospital in Bulgaria to offer patients treatment with the TomoTherapy® System. SBALO selected this system because it is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy.
Based on a CT scanner platform, the TomoTherapy® System provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients.
"The recent installations of Accuray technologies in Qatar, Latvia and Bulgaria indicate clinicians believe in the long-term benefits our devices can provide to their patients," says Lionel Hadjadjeba, corporate senior vice president, president worldwide commercial operations at Accuray. "We're committed to working with clinical teams around the world to ensure that with the CyberKnife® and TomoTherapy Systems, they can significantly and positively impact the way cancer is managed."
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market adoption of the company's products, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's report on Form 10-Q, filed on November 5, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.